SILENCE THERAP. SP.ADR/1 (XRP2) — Capital Reinvestment Ratio
SILENCE THERAP. SP.ADR/1 (XRP2) has a Capital Reinvestment Ratio of 0.20x as of December 2021, meaning it reinvests 0% of its operating cash flow (€9.19 Million) in capital expenditures (€1.80 Million). See XRP2 net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
SILENCE THERAP. SP.ADR/1 Capital Reinvestment Ratio (2021–2021)
This chart tracks SILENCE THERAP. SP.ADR/1's Capital Reinvestment Ratio across 1 annual periods. Check SILENCE THERAP. SP.ADR/1 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for SILENCE THERAP. SP.ADR/1 (2021–2021)
Year-by-year Capital Reinvestment Ratio for SILENCE THERAP. SP.ADR/1 from 2021 to 2021. For live market cap and broader valuation context, see how much is SILENCE THERAP. SP.ADR/1 worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.20x | €9.19 Million | €1.80 Million | — |